Jordi Ribera

Dr. Jordi Ribera

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
OMOscar Molina
Oscar Molina
ABAlex Bataller
Alex Bataller
NTNamitha Thampi
Namitha Thampi
JRJordi Ribera
Jordi Ribera
IGIsabel Granada
Isabel Granada
PMPablo Menendez
Pablo Menendez
Hypodiploidy with less than 40 chromosomes is a rare genetic abnormality in B-cell acute lymphoblastic leukemia (B-ALL). This condition can be classified based on modal chromosome number as low-hypodiploidy (30–39 chromosomes) and near-haploidy (24–29 chromosomes), with unique cytogenetic and mutational landscapes. Hypodiploid B-ALL with <40 chromosomes has an extremely poor outcome, with 5-year overall survival rates below 50% and 20% in childhood and adult B-ALL, respectively. Accordingly, this genetic feature represents an adverse prognostic factor in B-ALL and is associated with early relapse and therapy refractoriness. Notably, half of all patients with hypodiploid B-ALL with <40 chromosomes cases ultimately exhibit chromosome doubling of the hypodiploid clone, resulting in clones with 50–78 chromosomes. Doubled clones are often the major clones at diagnosis, leading to “masked hypodiploidy”, which is clinically challenging as patients can be erroneously classified as hyperdiploid B-ALL. Here, we summarize the main cytogenetic and molecular features of hypodiploid B-ALL subtypes, and provide a brief overview of the diagnostic methods, standard-of-care treatments and overall clinical outcome. Finally, we discuss molecular mechanisms that may underlie the origin and leukemogenic impact of hypodiploidy and may open new therapeutic avenues to improve survival rates in these patients.

9 January 2021 in Genes
Verified
Journal Article
Open access
PDF file
CGCelia González-Gil
Celia González-Gil
JRJordi Ribera
Jordi Ribera
JRJose-Maria Ribera
Jose-Maria Ribera
EGEulàlia Genescà
Eulàlia Genescà
Acute lymphoblastic leukemia (ALL) is a malignant clonal expansion of lymphoid hematopoietic precursors that exhibit developmental arrest at varying stages of differentiation. Similar to what occurs in solid cancers, transformation of normal hematopoietic precursors is governed by a multistep oncogenic process that drives initiation, clonal expansion and metastasis. In this process, alterations in genes encoding proteins that govern processes such as cell proliferation, differentiation, and growth provide us with some of the clearest mechanistic insights into how and why cancer arises. In such a scenario, deletions in the 9p21.3 cluster involving CDKN2A/ARF/CDKN2B genes arise as one of the oncogenic hallmarks of ALL. Deletions in this region are the most frequent structural alteration in T-cell acute lymphoblastic leukemia (T-ALL) and account for roughly 30% of copy number alterations found in B-cell-precursor acute lymphoblastic leukemia (BCP-ALL). Here, we review the literature concerning the involvement of the CDKN2A/B genes as a prognosis marker of good or bad response in the two ALL subtypes (BCP-ALL and T-ALL). We compare frequencies observed in studies performed on several ALL cohorts (adult and child), which mainly consider genetic data produced by genomic techniques. We also summarize what we have learned from mouse models designed to evaluate the functional involvement of the gene cluster in ALL development and in relapse/resistance to treatment. Finally, we examine the range of possibilities for targeting the abnormal function of the protein-coding genes of this cluster and their potential to act as anti-leukemic agents in patients.

26 August 2017 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
JRJordi Ribera
Jordi Ribera
LZLurdes Zamora
Lurdes Zamora
MMMireia Morgades
Mireia Morgades
MMMar Mallo
Mar Mallo
NSNeus Solanes
Neus Solanes
FHfor the Spanish PETHEMA Group and the Spanish Society of Hematology
for the Spanish PETHEMA Group and the Spanish Society of Hematology

24 July 2019 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
JRJordi Ribera
Jordi Ribera
LZLurdes Zamora
Lurdes Zamora
MMMireia Morgades
Mireia Morgades
SVSusana Vives
Susana Vives
IGIsabel Granada
Isabel Granada
SHSpanish Society Of Hematology
Spanish Society Of Hematology

27 March 2019 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JRJordi Ribera
Jordi Ribera
IGIsabel Granada
Isabel Granada
MMMireia Morgades
Mireia Morgades
SVSusana Vives
Susana Vives
EGEulàlia Genescà
Eulàlia Genescà
THthe PETHEMA Group, Spanish Society of Haematology
the PETHEMA Group, Spanish Society of Haematology

4 July 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
MFMaribel Forero-Castro
Maribel Forero-Castro
AMAdrián Montaño
Adrián Montaño
CRCristina Robledo
Cristina Robledo
AGAlfonso Garcia
Alfonso Garcia
JFJosé L Fuster
José L Fuster
Jesús María Hernández-RivasJesús María Hernández-Rivas
Jesús María Hernández-Rivas
The clonal basis of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is complex and not fully understood. Next-generation sequencing (NGS), array comparative genomic hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) were carried out in matched diagnosis–relapse samples from 13 BCP-ALL patients to identify patterns of genetic evolution that could account for the phenotypic changes associated with disease relapse. The integrative genomic analysis of aCGH, MLPA and NGS revealed that 100% of the BCP-ALL patients showed at least one genetic alteration at diagnosis and relapse. In addition, there was a significant increase in the frequency of chromosomal lesions at the time of relapse (p = 0.019). MLPA and aCGH techniques showed that IKZF1 was the most frequently deleted gene. TP53 was the most frequently mutated gene at relapse. Two TP53 mutations were detected only at relapse, whereas the three others showed an increase in their mutational burden at relapse. Clonal evolution patterns were heterogeneous, involving the acquisition, loss and maintenance of lesions at relapse. Therefore, this study provides additional evidence that BCP-ALL is a genetically dynamic disease with distinct genetic profiles at diagnosis and relapse. Integrative NGS, aCGH and MLPA analysis enables better molecular characterization of the genetic profile in BCP-ALL patients during the evolution from diagnosis to relapse.